cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arcus Biosciences Inc
8 own
2 watching
Current Price
$0
$-0.24
(-1.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,544M
52-Week High
52-Week High
39.75
52-Week Low
52-Week Low
16.74
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,544M
icon52-Week High39.75
icon52-Week Low16.74
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio--
What does the Arcus Biosciences Inc do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Read More
How much money does Arcus Biosciences Inc make?
News & Events about Arcus Biosciences Inc.
Business Wire
1month ago
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted four new employees options to purchase a total of 11,250 shares of the...
MarketWatch.com - GOOG
1month ago
New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs...
Zolmax
1month ago
Shares of Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) have been given an average rating of Moderate Buy by the nine brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy ...
PR Newswire
2 months ago
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies Optimism Building for Advancing Pancreatic Cancer Treatment Therapies PR Newswire PALM BEACH, Fla., Dec. 1, 2022 PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts...
Business Wire
2 months ago
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score...
Frequently Asked Questions
Frequently Asked Questions
What is Arcus Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Arcus Biosciences Inc shares?
plus_minus_icon
How can I buy Arcus Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Arcus Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arcus Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Arcus Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Arcus Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arcus Biosciences Inc?
plus_minus_icon
What percentage is Arcus Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arcus Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.24
(-1.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$24.97
$0.29 (1.18 %)
Morphic Holding Inc
Morphic Holding Inc
$37.32
$0.51 (1.39 %)
Replimune Group Inc
Replimune Group Inc
$28.40
$-0.23 (-0.79 %)
Bridgebio Pharma Inc
Bridgebio Pharma Inc
$11.35
$-0.46 (-3.90 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$24.97
$0.29 (1.18 %)
Morphic Holding Inc
Morphic Holding Inc
$37.32
$0.51 (1.39 %)
Replimune Group Inc
Replimune Group Inc
$28.40
$-0.23 (-0.79 %)
Bridgebio Pharma Inc
Bridgebio Pharma Inc
$11.35
$-0.46 (-3.90 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00